STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies*

	Item No	Recommendation	Page No
Title and abstract	1	(a) Indicate the study's design with a commonly used term in the title or	1,2
		the abstract	
		(b) Provide in the abstract an informative and balanced summary of what	2
		was done and what was found	
Introduction			
Background/rationale	2	Explain the scientific background and rationale for the investigation	3-4
		being reported	
Objectives	3	State specific objectives, including any prespecified hypotheses	4
Methods			
Study design	4	Present key elements of study design early in the paper	4-5
Setting	5	Describe the setting, locations, and relevant dates, including periods of	4-5
C			
Participants	6		4-5
Turrospunts			
Variables	7	• •	8
Data sources/	8*		6,7
measurement			
incusur ciricin			
Bias	9		response
			to
			reviewer
Study size	10	Explain how the study size was arrived at	8
Quantitative	11		8
variables			
Statistical methods	12		8
		(b) Describe any methods used to examine subgroups and interactions	N/A
		State specific objectives, including any prespecified hypotheses Present key elements of study design early in the paper Describe the setting, locations, and relevant dates, including periods of recruitment, exposure, follow-up, and data collection (a) Give the eligibility criteria, and the sources and methods of selection of participants Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Describe any efforts to address potential sources of bias received the eligibility criteria, and the sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group Describe any efforts to address potential sources of bias received the eligibility criteria, and the sources of bias received the eligibility criteria, and the sources and details of selection of methods of participants received the eligibility criteria, and received the sources and methods of selection of participants received the eligibility criteria, and relevant data collection Received the eligibility criteria, and the sources and methods of selection of participants received the eligibility criteria, and relevant data collection Received the eligiblity criteria, and the sources and methods of selection of participants received the eligiblity criteria, and the sources and methods of selection of participants received the eligiblity criteria, and the sources and methods of selection of participants received the eligiblity criteria, and the sources and methods of selection of participants received the eligiblity criteria, and the sources and methods of selection of participants received the eligiblity crite	7
			N/A
			N/A
Results			<u> </u>
Participants	13*	(a) Report numbers of individuals at each stage of study—ag numbers	8,24
Tarticipants	13	, ,	0,24
			8,24
			24
Descriptive data	14*	<u> </u>	22-23
Descriptive data	14.		22-23
			7
		(b) Indicate number of participants with missing data for each variable of interest	7
Outcome d-t-	15*		9.0
Outcome data	15*	Report numbers of outcome events or summary measures	8-9

Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	8-9
Walli Tesuits	10	estimates and their precision (eg, 95% confidence interval). Make clear	0-7
		which confounders were adjusted for and why they were included	
		(b) Report category boundaries when continuous variables were	N/A
		categorized	
		(c) If relevant, consider translating estimates of relative risk into absolute	N/A
		risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and interactions,	N/A
		and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	8-9
Limitations	19	Discuss limitations of the study, taking into account sources of potential	11-13
		bias or imprecision. Discuss both direction and magnitude of any	
		potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering objectives,	9-11, 13
		limitations, multiplicity of analyses, results from similar studies, and	
		other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	11-12
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	1
		study and, if applicable, for the original study on which the present	
		article is based	
		article is based	

^{*}Give information separately for exposed and unexposed groups.

Note: An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.